BVS vs SN.L
BVS: Bioventus is an orthopedic medical technology company focused on pain relief and musculoskeletal treatment through hyaluronic acid viscosupplements, bone growth stimulators, and emerging surgical and regenerative medicine platforms. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | BVS | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $14.38 | £10.74 | |
| Market cap as of 2026-08-24 | $1.2B | n/a | |
| P/E as of 2026-08-24 | 41.01 | n/a | |
| PEG as of 2026-08-24 | 3.20 | n/a | |
| Net margin as of 2026-08-24 | +4.9% | n/a | |
| Gross margin as of 2026-08-24 | +68.7% | n/a | |
| Operating margin as of 2026-08-24 | +9.9% | n/a | |
| ROE as of 2026-08-24 | +16.3% | n/a | |
| ROA as of 2026-08-24 | +4.2% | n/a | |
| Debt / equity as of 2026-08-24 | 1.49 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +1.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.5% | n/a | |
| Beta as of 2026-08-24 | 0.68 | n/a | |
| 1-year return as of 2026-08-21 close | +103.1% | -22.8% | BVS higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.